A collaborative approach to professional development on inclusive practices aligned to preschool mandates

Autor: Michelle L. Damiani, Brad V. Unick, Karen-Joy Schultz

Publikováno v: School-University Partnerships, Vol 17, Iss 3, Pp 303-321 (2024)

Purpose – Professional development (PD) is an essential component of continuing learning for in-service teachers. This paper discusses a school-based example of using the best practice of coaching in early childhood education supported by a profess

Externí odkaz: https://doaj.org/article/f7fc4bc07c6245a8b71260ebdaf251c2

Competency-based faculty development: applying transformations from lessons learned in competency-based medical education

Autor: Karen W Schultz, Klodiana Kolomitro, Sudha Koppula, Cheri H Bethune

Publikováno v: Canadian Medical Education Journal (2023)

Faculty development in medical education is often delivered in an ad hoc manner instead of being a deliberately sequenced program matched to data-informed individual needs. In this article, the authors, all with extensive experience in Faculty Develo

Externí odkaz: https://doaj.org/article/0b6a9cd364f240cba236b4b31f1278b2

A Comparison between Two Intervals of Daily Total End Range Time for Treatment of Proximal Interphalangeal Joint Flexion Contracture Using an Elastic Tension Digital Neoprene Orthosis

Autor: Vicenç Punsola-Izard, Aroa Casado, Nuria Carnicero, Elena Ozaes-Lara, Judit Mendieta-Zamora, Gemma Romera-Orfila, Karen S. Schultz, Manuel Llusà

Publikováno v: Journal of Clinical Medicine
Volume 12
Issue 5
Pages: 1987

Focusing on fingers with proximal interphalangeal joint flexion contractures, this study seeks to determine whether significant differences exist between the joint passive range of motion PROM improvement when receiving higher doses of daily total en

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b89d2091ebc8fd680fee03bcc7de3b
https://doi.org/10.3390/jcm12051987

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Autor: Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, Gregory S Sawicki, Philip Chang, Hildegarde Paz-Diaz, Jaime L Rubin, Yoojung Yang, Xingdi Hu, David J Pasta, Stefanie J Millar, Daniel Campbell, Xin Wang, Neil Ahluwalia, Caroline A Owen, Claire E Wainwright, Ronald L. Gibson, Steven M. Rowe, Noah Lechtzin, Richard C. Ahrens, Karen S. McCoy, Moira Aitken, Scott H. Donaldson, Kimberly Ann McBennett, Joseph M. Pilewski, Joanne Billings, Carlos Milla, Ronald Rubenstein, Daniel Brian Rosenbluth, Rachel Linnemann, Michael R. Powers, Christopher Fortner, Carla Anne Frederick, Theodore G. Liou, Philip Black, Janice Wang, John L. Colombo, Maria Berdella, Maria Veronica Indihar, Cynthia D. Brown, Michael Anstead, Lara Bilodeau, Leonard Sicilian, James Jerome Tolle, Kathryn Moffett, Samya Nasr, Jennifer Taylor-Cousar, Tara Lynn Barto, Nicholas Antos, John S. Rogers, Bryon Quick, Henry R. Thompson, Gregory Sawicki, Bruce Barnett, Robert L. Zanni, Thomas C. Smith, Karen D. Schultz, Claire Keating, Patrick Flume, Gregory J. Omlor, Alix Ashare, Karen Voter, Nighat Mehdi, Maria Gabriela Tupayachi Ortiz, Tonia E. Gardner, Steven R. Boas, Barbara Messore, Edith Zemanick, Raksha Jain, Michael McCarthy, Dana G. Kissner, Kapilkumar Patel, John McNamara, Julie Philley, Ariel Berlinski, Francisco J. Calimano, Terry Chin, Douglas Conrad, Cori Daines, Hengameh H. Raissy, Thomas G. Keens, Jorge E. Lascano, Bennie McWilliams, Brian Morrissey, Santiago Reyes, Subramanyam Chittivelu, Sabiha Hussain, Arvey Stone, James Wallace, Ross Klingsberg, Julie A. Biller, Stephanie Bui, Olaf Sommerburg, Elisabetta Bignamini, Mirella Collura, Alexander Moller, Donatello Salvatore, Chantal Belleguic, Lea Bentur, Ori Efrati, Eitan Kerem, Dario Prais, Esther Quintana Gallego, Peter Barry, Galit Livnat-Levanon, Jose Ramon Villa Asensi, David Stuart Armstrong, Oscar Asensio de la Cruz, Francis Gilchrist, Diana Elizabeth Tullis, Bradley Quon, Larry C. Lands, Nancy Morrison, Annick Lavoie, Barry Linnane, Okan Elidemir, Felix Ringshausen, Matthias Kappler, Helge Hebestreit, Jochen Mainz, Alexander Kiefer, Cordula Koerner-Rettberg, Doris Staab, Wolfgang Gleiber, Tacjana Pressler, Florian Stehling, Andreas Hector, Sivagurunathan Sutharsan, Lutz Naehrlich, Damian Downey, Jane Carolyn Davies, Robert Ian Ketchell, Mary Patricia Carroll, Simon Doe, Gordon MacGregor, Edward Fairbairn Nash, Nicholas Withers, Daniel Gavin Peckham, Martin James Ledson, Sonal Kansra, Timothy William Rayner Lee, Bertrand Delaisi, Gilles Rault, Jean Le Bihan, Dominique Hubert, Isabelle Fajac, Isabelle Sermet-Gaudelus, Marleen Bakker, Bert Arets, Christiane De Boeck, Raphael Chiron, Philippe Reix, Catherine Mainguy, Eva van Braeckel, Anne Malfroot, Isabelle Durieu, Nadine Desmazes Dufeu, Anne Prevotat, Renske van der Meer, Petrus Merkus, E.J.M. Weersink, Isabel Barrio Gomez-Aguero, Silvia Gartner, Amparo Sole Jover, Antonio Alvarez Fernandez, Desmond William Cox, Edward F. McKone, Barry James Plant, Hiranjan Selvadurai, Simon David Bowler, Claire Elizabeth Wainwright, Daniel Smith, Peter Gordon Middleton, John William Wilson, Sonia Volpi, Carla Colombo, Benedetta Fabrizzi, Vincenzina Lucidi, Federico Cresta, Salvatore Cucchiara, Ernst Eber, Helmut Ellemunter, Isidor Huttegger, Lena Hjelte, Christina Krantz, Marita Gilljam

Publikováno v: lancet. Respiratory medicine, 9(7), 733-746. Elsevier Limited
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5

Summary Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8–24 weeks in phase 3 clinical studies in participants

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf49af3de3f90b3a65bf102dbba3756b
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html

Contributors

Autor: Ingo Alig, John L. Battiste, Douglas H. Berry, Thorsten Bitsch, Ching-Hsuan Chang, Jennifer David, James J. Filliben, Sean Fowler, Henry K. Hardcastle, Arved Harding, Robert Hayes, Brian Hinderliter, Donald Hunston, Masayuki Ito, Carlos Juarez-Garcia, Karnav Kanuga, Hyun-Jin Koo, Thomas Kroth, Kai Kühne, Dirk Lellinger, Bernard H. Liu, Frank Malz, James E. Pickett, Adam L. Pintar, Jeffrey Quill, Marc Reinhardt, Karsten Rode, Beate Röder, Erik D. Sapper, Jan C. Schlothauer, Karen A. Schultz, Jill E. Seebergh, Pu-Jui Su, Lipiin Sung, Marc Wallmichrath, Stephanie S. Watson, Christopher C. White, Kenneth M. White, Kurt Wood, Huang Wu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6af72fb0ed48ab18e7731843a7465e6e
https://doi.org/10.1016/b978-0-323-49776-3.00021-0